Validating Single-Use Systems in Biopharma: Key Requirements and Emerging Expectations

Single-Use Systems (SUS) have become a fundamental component of modern biopharmaceutical manufacturing. Their flexibility, reduced cleaning requirements, and rapid deployment make them ideal for dynamic processes such as cell culture, buffer preparation, purification steps, and fill–finish operations.

However, as SUS rely on polymer-based materials, Quality and Validation teams must not only ensure robust functional validation but also consider the potential chemical risks associated with Extractables & Leachables (E&L).

Regulators increasingly expect manufacturers to demonstrate control over both dimensions — operational performance and material compatibility — making the validation of SUS a multidimensional task where quality, compliance, and E&L risk management converge.

1. Supplier Qualification and Material Traceability

The foundation of SUS validation begins with supplier qualification. Since SUS are manufactured using complex supply chains, Quality teams must ensure that vendors provide:

• Complete material specifications
• Certificate of compliance for process-contact components
• Change control mechanisms
• Robust quality systems and audit readiness

Traceability is critical. Regulators expect manufacturers to demonstrate full visibility into the materials that come into contact with process fluids. When components are preassembled, pre-sterilized, or sourced from multiple suppliers, the validation burden increases significantly.

2. Ensuring Fitness for Intended Use

Validating SUS is not just about confirming functionality — it is about proving that each component is suitable for its specific process application. This includes evaluating:

• Mechanical integrity (pressure, torque, sealing, tensile strength)
• Sterility assurance and sterilization compatibility
• Integrity testing before and after use
• Compatibility with process fluids, operating conditions, and mixing parameters

Regulators expect documented evidence that the SUS configuration used in manufacturing aligns with the conditions assessed during validation. Any deviation (e.g., different tubing type, new filter model, alternate connector) can require requalification or additional justification.

3. Quality Documentation and Inspection Readiness

A complete validation package must include clear, traceable documentation that supports decision-making. This typically involves:

• Design qualification (DQ) based on process requirements
• Installation qualification (IQ) including component identification
• Operational qualification (OQ) demonstrating functional performance
• Standard operating procedures for assembly, handling, and disposal
• Risk assessments aligned with ICH Q9(R1) principles

Auditors routinely request evidence that SUS have been evaluated systematically, that change controls are in place, and that Quality has visibility over supplier reliability and component consistency.

4. Where Extractables & Leachables (E&L) Strengthen the Validation Framework

While mechanical and functional validation ensure the system works as intended, they do not address the chemical risks associated with polymer-based materials. This is where Extractables & Leachables (E&L) assessments become a crucial complement to the overall validation strategy.

SUS materials can release chemical compounds under certain temperature, pH, and process conditions. Regulators increasingly expect manufacturers to demonstrate that these compounds:

• Are identified and assessed
• Pose no risk to product quality or patient safety
• Are evaluated using justified, traceable toxicological frameworks
• Are supported by appropriate supplier or custom studies

However, interpreting extractables datasets — often hundreds of pages — requires specialized expertise in both analytical chemistry and toxicology.

关于作者

订阅

绝无垃圾邮件。随时取消订阅。